SimonMed Imaging Partners with Lunit to Deliver Best-in-Class AI for Breast Cancer Detection
A Major Leap Forward in Patient Health and the Future of Mammography
PHOENIX, April 23, 2025 /PRNewswire/ -- SimonMed Imaging®, one of the largest and most advanced outpatient medical imaging providers in the United States, is proud to announce their partnership with Lunit, a global leader in AI-driven cancer diagnostics and therapeutics, to bring a new era of AI-powered breast cancer detection to patients across the country. The partnership marks a major milestone in SimonMed's mission to save lives through early detection.
SimonMed has selected Lunit INSIGHT DBT™, in combination with Volpara Analytics™, as the most advanced AI solution for breast cancer screening after an extensive evaluation of technologies on the market. This best-in-class software will now power SimonMed's Personalized Breast Cancer Detection (PBCD) service, designed to provide every patient with a precise, highly personalized, and data-driven screening experience.
"This is more than just an upgrade—it's an important step forward for our patient's health," said Dr. Sean Raj, Chief Innovation Officer at SimonMed Imaging and Fellow of The Society of Breast Imaging (FSBI) "We've evaluated a range of AI technologies, and Lunit's performance, speed, and clinical validation stood above the rest. This partnership enables us to offer the most precise and personalized mammogram experience to date—and when paired with our board-certified breast radiologists, we believe it offers the most advanced mammogram available today"
Lunit INSIGHT DBT is trained on millions of images and engineered to detect even the most subtle signs of breast cancer, improving both sensitivity and specificity. Integrated into SimonMed's national network of over 170 accredited centers and supported by more than 200 subspecialty-trained radiologists, this AI solution helps ensure earlier detection, faster turnaround times, and actionable insights for patients.
"This is the most advanced AI solution we've ever adopted," said Dr. John Simon, MD, Founder and CEO of SimonMed Imaging. "It reflects our unwavering commitment to providing every patient we see with the most accurate, affordable, and proactive care possible."
"SimonMed is leading by example," said Craig Hadfield, CEO of Volpara Health, a Lunit company bringing innovative AI solutions to the United States. "This is more than a technology upgrade—it's a transformation of care. With Volpara and Lunit, SimonMed is helping set a new standard for what modern high-quality breast screening should look like: data-driven, patient-focused, and grounded in clinical excellence."
For more details on SimonMed's Personalized Breast Cancer Detection and how it can benefit patients, visit simonmed.com.
About SimonMed
Headquartered in Scottsdale, Arizona, SimonMed is one of the largest outpatient medical imaging providers and radiology practices in the United States. SimonMed has approximately 170 sites across 11 states and over 200 subspecialty-trained radiologists. SimonMed offers the full modality of diagnostic scans, including 3T MRI, CT, ultrasound, 3-D mammography, PET/CT, nuclear medicine, DEXA, X-rays, among others. The company uses the newest, most advanced, diagnostic imaging technologies while maintaining affordability and accessibility. SimonMed is a worldwide leader in the clinical use of AI to improve diagnoses with one of the largest global deployments to enhance early breast cancer detection and in the evaluation of brain disorders. Through its simonONE division, SimonMed is also at the forefront of personalized imaging for the early diagnosis and treatment of disease. For more information, visit simonone.com and simonmed.com.
About Lunit
About Lunit Founded in 2013, Lunit (KRX:328130.KQ) is a medical AI company on a mission to conquer cancer through AI. Lunit harnesses AI-powered medical image analytics and biomarker analysis to ensure accurate diagnosis and optimal treatment for each cancer patient. The FDA-cleared Lunit INSIGHT suite for cancer screening serves over 4,800 medical institutions across 55+ countries. Lunit clinical studies have been published in top journals, including the Journal of Clinical Oncology and the Lancet Digital Health, and presented at global conferences such as the ASCO and RSNA. Headquartered in Seoul, South Korea, with a network of offices worldwide, Lunit leads the global fight against cancer. Discover more at lunit.io.
About Volpara
Volpara Health is on a mission to save families from cancer with AI-powered software that helps healthcare providers better understand cancer risk, guide personalized care decisions, and recommend additional imaging and interventions. Used in over 3,500 facilities by more than 9,500 technologists worldwide. Volpara's software impacts nearly 18M patients, supports over 3.6M annual cancer risk assessments, and integrates seamlessly with electronic health records and imaging systems. Volpara helps radiologists quantify dense breast tissue with precision and technologists produce mammograms that have optimal positioning, compression, and dose. Volpara software also streamlines operations to ease compliance and accreditation. Volpara, a Lunit company, is headquartered in Wellington, New Zealand, and has an office in Seattle. Volpara is the trusted partner of leading healthcare institutions globally. For more information, visit www.volparahealth.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/simonmed-imaging-partners-with-lunit-to-deliver-best-in-class-ai-for-breast-cancer-detection-302435715.html
SOURCE Lunit
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
01-06-2025
- Yahoo
BreastScreen Australia Density Reporting Rule is a Critical Step for Women says Volpara Health, the Leader in AI-assisted Breast Density Measurement
Volpara software is used to assess the breast density of more than 1 million Australian womenannually WELLINGTON, New Zealand, June 2, 2025 /PRNewswire/ -- Volpara Health, a Lunit a company and global leader in software for the early detection of breast cancer, today applauded the significant advancement in breast health management with BreastScreen Australia's new position on breast density reporting. This new guidance recommends that all BreastScreen services in Australia provide breast density information to clients, enhancing awareness and understanding of this critical risk factor. A Step Toward More Accurate and Personalised Breast Cancer Screening Volpara's Scorecard software is utilised to measure the breast density of over 1 million women annually across Australia, including in BreastScreen Victoria and BreastScreen South Australia. This comprehensive, AI-driven approach supports physicians in making consistent, objective assessments, helping to ensure that breast cancer risk is more accurately evaluated for each patient. Volpara's volumetric breast density assessment software, including its proprietary Volpara® TruDensity™ AI algorithm, provides consistent and precise breast density measurements. Cleared by the Therapeutic Goods Administration (TGA), FDA, Health Canada, and CE-marked in Europe, this technology has been validated in more than 400 scientific articles and research abstracts, underscoring its reliability and accuracy. "We've been collaborating with leading clinicians and researchers worldwide for over a decade to make critical information about breast composition and its link to breast cancer more accessible," said Craig Hadfield, CEO, Volpara Health. "The new guidelines from BreastScreen Australia validate our focus on applying tech and AI advancements to breast density and are a significant step forward in enhancing the experience and understanding for women and their healthcare providers. We encourage women to contact their local healthcare provider and ask how they assess breast density." Understanding Breast Density: A Critical Risk Factor Breast density is an important factor in both breast cancer detection and risk assessment. It has been linked to an increased risk of developing breast cancer, while also making it more challenging to detect cancer through mammography. In Australia, approximately 40% of women have dense breasts, including 12% with extremely dense breasts. As breast density increases, the accuracy of mammography decreases. Research published in Radiology reveals that mammography can miss up to 50% of cancers in women with the densest breast tissue. Since both dense breast tissue and tumours appear white on a mammogram, cancers are often concealed, potentially delaying diagnosis. Studies confirm that early detection rates improve significantly when women with very dense breasts receive additional imaging, such as ultrasound or MRI, as part of their regular screening regimen. The Path Forward: Embracing Personalised Screening Breast density information is also integrated into several risk models, which helps identify women at higher risk of breast cancer who may benefit from supplemental screening. Volpara Scorecard is the only commercial automated software validated for use in both the Tyrer-Cuzick 8 and CanRisk (BOADICEA) riskmodels, providing consistent and robust breast density measurements. With this new guidance, Volpara is poised to play an essential role in supporting risk assessment and personalised screening in Australia, further advancing the goal of improving outcomes for women. The importance of personalised screening has also been recognised by other Australian health bodies, with Medicare recently introducing reimbursement for high-risk breast MRI screening based on Tyrer-Cuzick 8 or CanRisk risk assessment. This marks a growing recognition of the need for tailored breast cancer screening strategies that consider individual risk factors, including breast density. About Volpara Health Volpara Health is on a mission to save families from cancer with AI-powered software that helps healthcare providers better understand cancer risk, guide personalized care decisions, and recommend additional imaging and interventions. Used in over 3,500 facilities by more than 9,500 technologists worldwide. Volpara's software impacts nearly 18M patients, supports over 3.6M annual cancer risk assessments, and integrates seamlessly with electronic health records and imaging systems. Volpara helps radiologists quantify dense breast tissue with precision and technologists produce mammograms with optimal positioning, compression, and dose. Volpara software also streamlines operations to ease compliance and accreditation. Volpara, a Lunit company, is headquartered in Wellington, New Zealand, and has an office in Seattle. Volpara is the trusted partner of leading healthcare institutions globally. For more information, visit Logo - View original content: SOURCE Volpara Health Error in retrieving data Sign in to access your portfolio Error in retrieving data
Boston Globe
30-05-2025
- Boston Globe
AI-based mammography is here, and it has a trust problem
Enthusiasm is growing for the technology, as prospective trials conducted in Europe suggest that some AI tools can detect more cancers than radiologists alone. But beyond radiology networks that are implementing their own algorithms, many imaging centers and the radiologists who work for them are still skeptical. Advertisement 'It'll take time for us to really gain a lot of trust and confidence in it,' said Manisha Bahl, a breast radiologist at Massachusetts General Hospital, which is currently testing several AI-based tools for mammography in a head-to-head study. One large Advertisement Radiologists were much less likely to call patients for follow-up when their mammogram was flagged by the AI than when it was flagged by a human radiologist — even though the AI-flagged cases were more likely to be cancerous. If both members of a human-AI pair flagged a case for possible malignancy, only 39 percent of patients were called back. If it was two radiologists that flagged a case, callbacks shot up to 57 percent. The researchers used technology from South Korean developer Lunit, which also partly funded the study. 'Providing a superior performing algorithm doesn't actually necessarily improve human performance,' said Adam Rodman, a clinical reasoning researcher and practicing internist who co-directs the iMED initiative at Beth Israel Deaconess Medical Center. 'This study does a really good job at explaining why that is, and it's trust.' It's a common refrain for breast radiologists, who have been burned by technology before. Computer-aided detection tools for mammograms became standard starting in the 1980s, but in the long run, they never improved cancer detection or recall rates. 'We have to be very careful what we do with AI once it's out in the wild,' said Etta Pisano, chief research officer at the American College of Radiology, at the meeting of the Radiological Society of North America in December. Advertisement Performance for breast cancer AI — which marks or annotates suspicious lesions on a mammogram and provides a score or some indication of the likelihood of malignancy — is typically reported based on how well it identifies cancers in databases of old mammograms that have been previously screened by human radiologists. But in practice, that performance can vary significantly from center to center and radiologist to radiologist. The radiologist's level of trust, the way the software is integrated into their With all those variables, how can a radiologist make sure that they're using AI the most effective way? 'The answer is, nobody knows,' said Rodman. Normally, Bahl, the radiologist at Mass General, opens up a mammogram and interprets it entirely on her own before she activates any AI-based image processing. That's to cut down on the risk of automation bias — where she learns to rely too much on the machine. That approach makes sense for radiologists who trust their professional judgement more than a new tool, and it aligns with surveys of patients that suggest they typically want a doctor making the final call on image analysis, said Sanjay Aneja, a radiation oncologist at Yale Cancer Center who studies mammography AI. But that approach doesn't fulfill AI's other main promise: the potential for efficiency. 'If anything, it might be a little bit less efficient,' said Aneja. With skilled radiologists in shortage, AI will ideally help them work smarter and faster — which means looking at the algorithm's output upfront. Advertisement At radiology practices that are more aggressively leaning into mammogram AI, 'radiologists gain confidence and start to look earlier in the process,' said Chris McKinney, director of North American sales for Lunit. That kind of comfort doesn't emerge unless radiologists are getting regular practice with a new system — and adoption of the tools is inconsistent, since they aren't reimbursed by insurance. Instead, most practices deploying the tools ask patients to pay a cash fee of $40 to $90 for an AI add-on. At the top-adopting practice within Rezolut, a network of more than 40 US radiology practices that use Lunit's breast AI system, about 40 percent of patients opt to pay. 'Every radiologist is going to have to work with the AI product and get more comfortable with it and then utilize it individually,' said Stamatia Destounis, chair of the American College of Radiology's breast imaging commission. 'I don't think everyone's going to use it the same way.' But 'practice makes perfect' isn't enough for many AI researchers and physicians, who want more explicit guidance when it comes to appropriate deployment of these tools as they become more widely used. 'The problem is that there's actually very little guardrails with a lot of these devices as they get put out there,' said Aneja. Imaging quality can vary significantly between radiology practices, for example. 'There's very few algorithms that say, 'This image is of poor quality, can't evaluate it,'' said Aneja. 'We want an algorithm to be able to say what they don't know.' Advertisement Chiara Corti, an oncologist from Italy and clinical fellow at Dana-Farber, calls for more disclosure of the race and ethnicity of patients whose mammograms were used to train AI tools to ensure accuracy across groups. (ACR's AI The performance — and relative value — of an AI tool also depends on the radiologists who are using it. Not every radiologist is an expert in reading mammograms, and 'one of the biggest benefits of AI is to disseminate that level of knowledge,' said Aneja. To ensure radiology practices use this new generation of algorithms in a way that drives better cancer outcomes, they need more real-world, prospective research in the US 'We need to see those human interactions,' said Destounis. 'It's impossible to deduce from a study going back in time how every radiologist is going to interact with the AI system in practice, daily.' A 2024 Advertisement That kind of real-world evidence is one of the goals of a program out of ARPA-H called ACTR, for Advancing Clinical Trial Readiness. Pisano, the program's director, said at the December RSNA meeting that ACTR planned to test AI products in real-world, pragmatic trials out of imaging centers across the country, most likely starting with trials of breast cancer screening algorithms that could include hundreds of thousands of mammograms. The trials, she said at the time, were planned to start this spring. They have yet to be announced.
Yahoo
23-04-2025
- Yahoo
SimonMed Imaging Partners with Lunit to Deliver Best-in-Class AI for Breast Cancer Detection
A Major Leap Forward in Patient Health and the Future of Mammography PHOENIX, April 23, 2025 /PRNewswire/ -- SimonMed Imaging®, one of the largest and most advanced outpatient medical imaging providers in the United States, is proud to announce their partnership with Lunit, a global leader in AI-driven cancer diagnostics and therapeutics, to bring a new era of AI-powered breast cancer detection to patients across the country. The partnership marks a major milestone in SimonMed's mission to save lives through early detection. SimonMed has selected Lunit INSIGHT DBT™, in combination with Volpara Analytics™, as the most advanced AI solution for breast cancer screening after an extensive evaluation of technologies on the market. This best-in-class software will now power SimonMed's Personalized Breast Cancer Detection (PBCD) service, designed to provide every patient with a precise, highly personalized, and data-driven screening experience. "This is more than just an upgrade—it's an important step forward for our patient's health," said Dr. Sean Raj, Chief Innovation Officer at SimonMed Imaging and Fellow of The Society of Breast Imaging (FSBI) "We've evaluated a range of AI technologies, and Lunit's performance, speed, and clinical validation stood above the rest. This partnership enables us to offer the most precise and personalized mammogram experience to date—and when paired with our board-certified breast radiologists, we believe it offers the most advanced mammogram available today" Lunit INSIGHT DBT is trained on millions of images and engineered to detect even the most subtle signs of breast cancer, improving both sensitivity and specificity. Integrated into SimonMed's national network of over 170 accredited centers and supported by more than 200 subspecialty-trained radiologists, this AI solution helps ensure earlier detection, faster turnaround times, and actionable insights for patients. "This is the most advanced AI solution we've ever adopted," said Dr. John Simon, MD, Founder and CEO of SimonMed Imaging. "It reflects our unwavering commitment to providing every patient we see with the most accurate, affordable, and proactive care possible." "SimonMed is leading by example," said Craig Hadfield, CEO of Volpara Health, a Lunit company bringing innovative AI solutions to the United States. "This is more than a technology upgrade—it's a transformation of care. With Volpara and Lunit, SimonMed is helping set a new standard for what modern high-quality breast screening should look like: data-driven, patient-focused, and grounded in clinical excellence." For more details on SimonMed's Personalized Breast Cancer Detection and how it can benefit patients, visit About SimonMed Headquartered in Scottsdale, Arizona, SimonMed is one of the largest outpatient medical imaging providers and radiology practices in the United States. SimonMed has approximately 170 sites across 11 states and over 200 subspecialty-trained radiologists. SimonMed offers the full modality of diagnostic scans, including 3T MRI, CT, ultrasound, 3-D mammography, PET/CT, nuclear medicine, DEXA, X-rays, among others. The company uses the newest, most advanced, diagnostic imaging technologies while maintaining affordability and accessibility. SimonMed is a worldwide leader in the clinical use of AI to improve diagnoses with one of the largest global deployments to enhance early breast cancer detection and in the evaluation of brain disorders. Through its simonONE division, SimonMed is also at the forefront of personalized imaging for the early diagnosis and treatment of disease. For more information, visit and About Lunit About Lunit Founded in 2013, Lunit (KRX: is a medical AI company on a mission to conquer cancer through AI. Lunit harnesses AI-powered medical image analytics and biomarker analysis to ensure accurate diagnosis and optimal treatment for each cancer patient. The FDA-cleared Lunit INSIGHT suite for cancer screening serves over 4,800 medical institutions across 55+ countries. Lunit clinical studies have been published in top journals, including the Journal of Clinical Oncology and the Lancet Digital Health, and presented at global conferences such as the ASCO and RSNA. Headquartered in Seoul, South Korea, with a network of offices worldwide, Lunit leads the global fight against cancer. Discover more at About Volpara Volpara Health is on a mission to save families from cancer with AI-powered software that helps healthcare providers better understand cancer risk, guide personalized care decisions, and recommend additional imaging and interventions. Used in over 3,500 facilities by more than 9,500 technologists worldwide. Volpara's software impacts nearly 18M patients, supports over 3.6M annual cancer risk assessments, and integrates seamlessly with electronic health records and imaging systems. Volpara helps radiologists quantify dense breast tissue with precision and technologists produce mammograms that have optimal positioning, compression, and dose. Volpara software also streamlines operations to ease compliance and accreditation. Volpara, a Lunit company, is headquartered in Wellington, New Zealand, and has an office in Seattle. Volpara is the trusted partner of leading healthcare institutions globally. For more information, visit View original content to download multimedia: SOURCE Lunit
